A Phase 2 interventional study of Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) and Zibotentan + placebo (placebo matching dapagliflozin tablet) in Liver Cirrhosis, sponsored by AstraZeneca. Completed at 34 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Liver Cirrhosis by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Liver Cirrhosis · AstraZeneca.
Among the 11 studies in Liver Cirrhosis by AstraZeneca, this one is the 4th largest by enrollment, is one of 3 that started in 2024, is one of 6 in phase 2, and was the 4th registered.
1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →1 of the 11 studies in Liver Cirrhosis by AstraZeneca is open now, in 2 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is close to the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 40 across the 11 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
1 of the studies in Liver Cirrhosis by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07610837AstraZenecaStudy of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis | 2027-07-07 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Liver Cirrhosis by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase IIb multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin and zibotentan monotherapy as compared to placebo in patients with cirrhosis.
The study is designed to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin in combination and zibotentan monotherapy as compared to placebo in patients with cirrhosis with or without a history of decompensation. The study will be conducted in approximately 52 study centers in North America, Asia and Europe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
≥ 18 and ≤ 80 years of age at the time of signing the .
Clinical and/or histological diagnosis of cirrhosis.
Note: Either history of decompensation or compensated cirrhosis with signs of CSPH, including varices at endoscopy or collaterals at imaging (within 12 months prior to screening), and/or liver stiffness using vibration controlled elastography, liver stiffness > 25 kPa or > 21 kPa, and \< 150 × 10\^99 (at time of screening).
Model for end stage liver disease score (MELD) \< 15.
score \< 10.
No ascites or ascites up to grade 2 without change in diuretic treatment within the last month prior to first dose of study intervention and no paracentesis within the last month.
No evidence of worsening of hepatic function (eg, no change in signs, symptoms, or laboratory parameters of hepatic disease status) within the last month prior to dosing, as determined by the investigator or usual practitioner.
No current or prior (within 1 month of enrolment) medical treatment with an SGLT2 inhibitor or endothelin receptor antagonist.
On no or a stable dose of beta blockers, with no major dose changes within 1 month prior to the first dose of study intervention.
Males or females of non-:
Male participants must be surgically sterile, abstinent, or must use in conjunction with their female partner a highly effective method of from the time they sign the informed consent document and for 3 months after the last dose of study intervention to prevent pregnancy in a partner. In addition, the male participant should use a condom for the duration of the study and for 3 months after the last dose of study intervention. Male participants must not donate or bank sperm during the same period.
Highly effective birth control methods are defined as those that can achieve a failure rate of less than 1% per year when used consistently and correctly.
Female participants must be of non-childbearing potential confirmed at screening by fulfilling one of the following criteria:
: defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments; and also FSH levels in the post-menopausal range by central laboratory (Note: The post-menopausal range must be checked against the specific FSH assay used). In the absence of 12 months of amenorrhoea, a single FSH measurement is insufficient to define post-menopausal criteria. In case of perimenopause or infrequent periods with variable levels of FSH, women should be considered of childbearing potential and, therefore, not eligible for participation in this study.
Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation.
Female participants must have a negative pregnancy test at screening and must not be lactating.
Capable of giving signed informed consent as described in Appendix A, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Provision of signed and dated, written ICF prior to any mandatory study-specific procedures, sampling, and analyses.
Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form prior to collection of samples for optional genomics initiative research that supports Genomic Initiative.
Exclusion criteria:
Any evidence of a disease, which in the investigator's opinion makes it undesirable for the participant to participate in the study.
/transaminase or AST ≥ 150 U/L and/or total
≥ 3 × .
> 1.7.
Serum/plasma levels of albumin ≤ 28 g/L.
count \< 50 × 109L.
Acute kidney injury (AKI) within 3 months of screening.
History of encephalopathy of West Haven Grade 2 or higher
History of variceal haemorrhage within 6 months prior to screening.
Any history of hepatocellular carcinoma.
Any history of portal venous thrombosis.
Liver transplant or expected liver transplantation within 6 months of screening.
History of TIPS or a planned TIPS within 6 months from enrolment into the study.
Positive alcohol breath test or screen for drugs of abuse (excluding drugs prescribed by the participants' usual physician) at screening.
Ongoing or history of significant use of alcohol expected to preclude correct adherence to study procedures (For details, refer to Section 5.3.2).
Active treatment for within the last 1 year or anti-viral therapy for less than 1 year.
Active urinary tract infection or genital infection.
Uncontrolled diabetes mellitus ( > 8.5% or > 69 mmol/mol within the last month).
Participants with T1DM.
Renal transplant or chronic renal replacement therapy or short-term dialysis within the previous 6 months.
\< 60 mL/min/1.73m2 (eGFRcr[AS]).
Acute coronary syndrome events within 3 months prior to screening.
Orthostatic hypotension or hypotension (systolic blood pressure \< 95 mmHg or diastolic blood pressure \< 60 mmHg).
functional heart failure Class III or IV or patients with unstable heart failure requiring hospitalisation for optimisation of heart failure treatment and who are not yet stable on heart failure therapy within 6 months prior to screening.
Heart failure due to cardiomyopathies that would primarily require specific other treatment.
High output heart failure (eg, due to hyperthyroidism or Paget's disease).
Heart failure due to primary cardiac valvular disease/dysfunction, severe functional mitral or tricuspid valve insufficiency, or planned cardiac valve repair/replacement.
Participants treated with strong inhibitor or strong or moderate CYP3A4 inducer within 14 days (St. John's Wort: 21 days) of study intervention administration; this includes grapefruit and grapefruit juice, if consumed more often than occasionally, or, in larger quantities.
History or ongoing allergy/, as judged by the investigator, to SGLT2 inhibitors (eg, dapagliflozin, canagliflozin, empagliflozin), zibotentan, or drugs with a similar chemical structure to zibotentan.
Any clinically significant chronic disease or disorder (eg, cardiovascular, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, psychiatric, major physical impairment) which, as judged by the investigator, might put the participant at risk because of participation in the study, or probable alternative primary reason for participant's symptoms in judgment of investigator.
Acute liver injury caused by drug toxicity or by an infection.
Implanted electronic device such as pacemaker.
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study centre).
Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Male participant in a sexually active relation with pregnant or breastfeeding partner.
Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Exclusion Criteria for Participants Consenting to Optional Genetic Sampling:
Previous bone marrow transplant.
Non-leukocyte depleted whole blood transfusion in 120 days of genetic sample collection.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks
Drug: Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)
Participants will receive once daily zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks
Drug: Zibotentan + placebo (placebo matching dapagliflozin tablet)
Participants will receive once daily zibotentan capsule + dapagliflozin tablet 10 mg for 6 weeks
Drug: Zibotentan + dapagliflozin
placebo capsule (matching zibotentan capsule) placebo tablet (matching dapagliflozin tablet)
zibotentan capsule placebo tablet (matching dapagliflozin tablet)
Drug pages: ZD4054 · Dapagliflozin
zibotentan capsule dapagliflozin 10 mg tablet
Cumulative Number of Subjects With Any of the Components of the Composite Endpoint: >2kg Increase in Body Weight (Office-based), >2 L Increase in Total Body Water, Increase in 2 or More Loop-diuretic Equivalents, Fluid Retention Adverse Event (AE)
Cumulative number of subjects with event of composite fluid retention endpoint
Time frame: baseline to Week 6
Change From Baseline in Body Weight
Change in site body weight
Time frame: at Week 6
Change From Baseline in Body Fat Mass
Time frame: at Week 6
Change From Baseline in Total Body Water
Time frame: at Week 6
Change From Baseline in Extracellular Water Volume
Time frame: at Week 6
Change From Baseline in Intracellular Water Volume
Time frame: at Week 6
Change in Body Weight (kg) Over Time Course of Study
Change in home body weight
Time frame: at Week 6
Change in Total Dosage of Loop-diuretic Equivalents Use
One loop-diuretic equivalent = 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide = 50 mg ethacrynic acid. In Japan, one loop-diuretic equivalent = 40 mg furosemide = 8 mg torsemide = 60 mg azosemide.
Time frame: at Week 6
Cumulative Number of Subjects With Either of the Two Components of This Composite: 1. >3 L Increase in Total Body Water Volume From Baseline to Week 6 2. Increase in 3 or More Loop-diuretics Equivalents Use
Cumulative number of subjects with event of composite and the components of total body water and total dosage of loop-diuretic equivalents
Time frame: from baseline to Week 6
Absolute Change in Systolic Blood Pressure
Time frame: at Week 6
Absolute Change in Diastolic Blood Pressure
Time frame: at Week 6
The first participant was enrolled on February 2024 and the last participant was enrolled in September 2024.
| Milestone | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Started | 24 | 25 | 24 |
| Treated | 24 | 24 | 24 |
| Completed | 20 | 24 | 22 |
| Not completed | 4 | 1 | 2 |
| Withdrew: Withdrawal by subject | 3 | 0 | 2 |
| Withdrew: All other reasons apart from specified | 1 | 0 | 0 |
| Withdrew: Randomised but not started treatment | 0 | 1 | 0 |
Cumulative number of subjects with event of composite fluid retention endpoint
| Participants | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Cumulative Number of Subjects With Any of the Components of the Composite Endpoint: >2kg Increase in Body Weight (Office-based), >2 L Increase in Total Body Water, Increase in 2 or More Loop-diuretic Equivalents, Fluid Retention Adverse Event (AE) | 14 | 14 | 6 |
Change in site body weight
| kg | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Change From Baseline in Body Weight | -1.08 (-1.88 to -0.28) | 0.64 (-0.11 to 1.39) | -0.53 (-1.31 to 0.24) |
| kg | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Change From Baseline in Body Fat Mass | -1.68 (-2.43 to -0.94) | -0.23 (-0.93 to 0.48) | -0.30 (-1.03 to 0.42) |
| L | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Change From Baseline in Total Body Water | 0.36 (-0.22 to 0.94) | 0.66 (0.12 to 1.21) | -0.36 (-0.92 to 0.21) |
| L | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Change From Baseline in Extracellular Water Volume | 0.38 (0.09 to 0.66) | 0.38 (0.11 to 0.65) | -0.15 (-0.43 to 0.13) |
| L | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Change From Baseline in Intracellular Water Volume | 0.08 (-0.24 to 0.40) | 0.30 (0 to 0.60) | -0.19 (-0.50 to 0.12) |
Change in home body weight
| kg | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Change in Body Weight (kg) Over Time Course of Study | -1.754 (-2.541 to -0.967) | 0.021 (-0.692 to 0.734) | -1.256 (-2.077 to -0.435) |
One loop-diuretic equivalent = 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide = 50 mg ethacrynic acid. In Japan, one loop-diuretic equivalent = 40 mg furosemide = 8 mg torsemide = 60 mg azosemide.
| Loop-diuretic *mg* equivalent | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Change in Total Dosage of Loop-diuretic Equivalents Use | 1.282 (-2.045 to 4.609) | 6.340 (3.104 to 9.576) | 1.338 (-1.953 to 4.629) |
Cumulative number of subjects with event of composite and the components of total body water and total dosage of loop-diuretic equivalents
| Participants | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Cumulative Number of Subjects With Either of the Two Components of This Composite: 1. >3 L Increase in Total Body Water Volume From Baseline to Week 6 2. Increase in 3 or More Loop-diuretics Equivalents Use | 7 | 9 | 2 |
| mmHg | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Absolute Change in Systolic Blood Pressure | -12.0 (-16.1 to -7.9) | -2.6 (-6.5 to 1.2) | -0.1 (-4.1 to 3.9) |
| mmHg | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Absolute Change in Diastolic Blood Pressure | -9.1 (-11.3 to -6.8) | -2.5 (-4.7 to -0.3) | 1.8 (-0.5 to 4.0) |
Collected over Adverse events reported are adverse events with an onset date on or after the date of first dose of IP and until end of study for each participant which in general was 6 weeks treatment period and 2 weeks follow-up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zibo/Dapa | 0/24 (0%) | 1/24 (4.2%) | 14/24 (58.3%) |
| Zibo | 0/24 (0%) | 2/24 (8.3%) | 15/24 (62.5%) |
| Placebo | 0/24 (0%) | 1/24 (4.2%) | 4/24 (16.7%) |
| Event | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/24 | 2/24 | 0/24 |
| AscitesGastrointestinal disorders | 0/24 | 0/24 | 1/24 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 1/24 | 0/24 | 0/24 |
| Event | Zibo/Dapa | Zibo | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 5/24 | 6/24 | 1/24 |
| Oedema peripheralGeneral disorders | 2/24 | 5/24 | 1/24 |
| Fluid retentionMetabolism and nutrition disorders | 3/24 | 1/24 | 0/24 |
| Orthostatic hypotensionVascular disorders | 3/24 | 2/24 | 0/24 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/24 | 3/24 | 0/24 |
| AscitesGastrointestinal disorders | 1/24 | 3/24 | 0/24 |
| Weight increasedInvestigations | 2/24 | 3/24 | 2/24 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/24 | 0/24 | 0/24 |
| ConstipationGastrointestinal disorders | 2/24 | 1/24 | 0/24 |
| Dry mouthGastrointestinal disorders | 2/24 | 0/24 | 0/24 |
Randomised subjects who received at least one dose of treatment.
| Age, Continuous(Years) | Zibo/Dapa | Zibo | Placebo | Total |
|---|---|---|---|---|
| Mean | 60.2 ± 11.4 | 59.5 ± 8.9 | 62.6 ± 8.4 | 60.8 ± 9.6 |
| Sex: Female, Male(Participants) | Zibo/Dapa | Zibo | Placebo | Total |
|---|---|---|---|---|
| Female | 6 | 8 | 7 | 21 |
| Male | 18 | 16 | 17 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Zibo/Dapa | Zibo | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 1 | 8 |
| Not Hispanic or Latino | 20 | 21 | 23 | 64 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Zibo/Dapa | Zibo | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 4 | 4 | 4 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 20 | 20 | 20 | 60 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Ran from Feb 2024 to primary completion in Dec 2024, 9 months.
Results were first posted in Jan 2026, 1 year 1 month after primary completion.
Of 28 industry-sponsored phase 2 interventional studies under Liver Cirrhosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 27. This study's 9 months is below that.
Counting every sponsor, half of 55 studies reached it within 27 months; a quarter within 19 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: ZD4054 · Dapagliflozin